Prognostic Factors for Adrenocortical Carcinoma Outcomes

Prognostic Factors for Adrenocortical Carcinoma Outcomes

Adrenocortical carcinoma (ACC) is an aggressive tumor characterized by a high recurrence rate and poor response to treatment. This study analyzes a consecutive series of ACC patients to evaluate the prognostic value of various clinical and pathological characteristics. We retrospectively evaluated 3...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in endocrinology (Lausanne) 2016-07, Vol.7, p.99-99
Hauptverfasser: Scollo, Claudia, Russo, Marco, Trovato, Maria Antonietta, Sambataro, Daniela, Giuffrida, Dario, Manusia, Mario, Sapuppo, Giulia, Malandrino, Pasqualino, Vigneri, Riccardo, Pellegriti, Gabriella
Format: Artikel
Sprache:eng
Schlagworte:
Endocrinology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 99
container_issue
container_start_page 99
container_title Frontiers in endocrinology (Lausanne)
container_volume 7
creator Scollo, Claudia
Russo, Marco
Trovato, Maria Antonietta
Sambataro, Daniela
Giuffrida, Dario
Manusia, Mario
Sapuppo, Giulia
Malandrino, Pasqualino
Vigneri, Riccardo
Pellegriti, Gabriella
description Adrenocortical carcinoma (ACC) is an aggressive tumor characterized by a high recurrence rate and poor response to treatment. This study analyzes a consecutive series of ACC patients to evaluate the prognostic value of various clinical and pathological characteristics. We retrospectively evaluated 32 ACC patients followed at our Medical Center from 1997 to 2015 and evaluated the prognostic value of age at diagnosis, gender, tumor functional status, stage, and type of treatment with respect to overall survival (OS) and disease-free survival (DFS), as determined by Kaplan-Meier curves. ACC was associated with hormonal overproduction in 50% of cases, and patients with isolated hyperandrogenism had a better prognosis. Recurrence was observed in 12/26 (46.2%) patients with no evidence of disease after surgery. Tumor size [hazard ratio (HR) 1.32, 95% confidential intervals (CI) 1.12-1.64; p = 0.007], ki-67 (HR 1.06, 95% CI 1.02-1.11; p = 0.009) and advanced stage at diagnosis (III-IV) (HR 6.51, 95% CI 1.65-24.68; p = 0.006) were associated with recurrence in the 26 R0 patients in the univariate analysis. Advanced stage was an independent risk factor for recurrence in the multivariate analysis (HR 8.10, 95% CI 1.55-41.35; p = 0.01). Five-year survival was 40.0%. Positive resection margins (HR 10.61, 95% CI 3.02-38.31; p = 
doi_str_mv 10.3389/fendo.2016.00099
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4958635</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1810555237</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-7a868430f39e07a6897ad8a4ce4bc8b82b55ca64f00f48fe6f2eb71f616007853</originalsourceid><addsrcrecordid>eNpVkM9LwzAUx4MobszdPUmPXjpfmh9NLsIYToXBPOg5pGkyK20zk1bwv7fbdMzTe_D98R4fhK4xzAgR8s7ZtvSzDDCfAYCUZ2iMOadpRmR2frKP0DTGj8ECFLCU4hKNspwBxcDHSLwEv2l97CqTLLXpfIiJ8yGZl8G23vgwCLpOFjqYqvWNTtZ9Z3xj4xW6cLqOdvo7J-ht-fC6eEpX68fnxXyVGiJ5l-ZacEEJOCIt5JoLmetSaGosLYwoRFYwZjSnDsBR4Sx3mS1y7DjmALlgZILuD73bvmhsaWzbBV2rbagaHb6V15X6r7TVu9r4L0UlE5zsCm5_C4L_7G3sVFNFY-tat9b3UWGBgTGWkXywwsFqgo8xWHc8g0HtmKs9c7VjrvbMh8jN6XvHwB9h8gPwiH54</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1810555237</pqid></control><display><type>article</type><title>Prognostic Factors for Adrenocortical Carcinoma Outcomes</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Scollo, Claudia ; Russo, Marco ; Trovato, Maria Antonietta ; Sambataro, Daniela ; Giuffrida, Dario ; Manusia, Mario ; Sapuppo, Giulia ; Malandrino, Pasqualino ; Vigneri, Riccardo ; Pellegriti, Gabriella</creator><creatorcontrib>Scollo, Claudia ; Russo, Marco ; Trovato, Maria Antonietta ; Sambataro, Daniela ; Giuffrida, Dario ; Manusia, Mario ; Sapuppo, Giulia ; Malandrino, Pasqualino ; Vigneri, Riccardo ; Pellegriti, Gabriella</creatorcontrib><description>Adrenocortical carcinoma (ACC) is an aggressive tumor characterized by a high recurrence rate and poor response to treatment. This study analyzes a consecutive series of ACC patients to evaluate the prognostic value of various clinical and pathological characteristics. We retrospectively evaluated 32 ACC patients followed at our Medical Center from 1997 to 2015 and evaluated the prognostic value of age at diagnosis, gender, tumor functional status, stage, and type of treatment with respect to overall survival (OS) and disease-free survival (DFS), as determined by Kaplan-Meier curves. ACC was associated with hormonal overproduction in 50% of cases, and patients with isolated hyperandrogenism had a better prognosis. Recurrence was observed in 12/26 (46.2%) patients with no evidence of disease after surgery. Tumor size [hazard ratio (HR) 1.32, 95% confidential intervals (CI) 1.12-1.64; p = 0.007], ki-67 (HR 1.06, 95% CI 1.02-1.11; p = 0.009) and advanced stage at diagnosis (III-IV) (HR 6.51, 95% CI 1.65-24.68; p = 0.006) were associated with recurrence in the 26 R0 patients in the univariate analysis. Advanced stage was an independent risk factor for recurrence in the multivariate analysis (HR 8.10, 95% CI 1.55-41.35; p = 0.01). Five-year survival was 40.0%. Positive resection margins (HR 10.61, 95% CI 3.02-38.31; p = &lt; 0.001), ki-67 (HR 1.04, 95% CI 1.01-1.07; p = 0.01) and advanced stage (HR 11.31, 95% CI 1.45-87.76; p = 0.02) were associated with poor survival in all 32 patients, but only positive resection margins were an independent predictor of mortality in the multivariate analysis (HR 6.22, 95% CI 1.44-26.05; p = 0.01). ACC has a poor prognosis with a high recurrence rate. Tumor stage at diagnosis and the completeness of surgical excision are the most relevant prognostic factors.</description><identifier>ISSN: 1664-2392</identifier><identifier>EISSN: 1664-2392</identifier><identifier>DOI: 10.3389/fendo.2016.00099</identifier><identifier>PMID: 27504106</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Endocrinology</subject><ispartof>Frontiers in endocrinology (Lausanne), 2016-07, Vol.7, p.99-99</ispartof><rights>Copyright © 2016 Scollo, Russo, Trovato, Sambataro, Giuffrida, Manusia, Sapuppo, Malandrino, Vigneri and Pellegriti. 2016 Scollo, Russo, Trovato, Sambataro, Giuffrida, Manusia, Sapuppo, Malandrino, Vigneri and Pellegriti</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-7a868430f39e07a6897ad8a4ce4bc8b82b55ca64f00f48fe6f2eb71f616007853</citedby><cites>FETCH-LOGICAL-c396t-7a868430f39e07a6897ad8a4ce4bc8b82b55ca64f00f48fe6f2eb71f616007853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958635/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958635/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27504106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scollo, Claudia</creatorcontrib><creatorcontrib>Russo, Marco</creatorcontrib><creatorcontrib>Trovato, Maria Antonietta</creatorcontrib><creatorcontrib>Sambataro, Daniela</creatorcontrib><creatorcontrib>Giuffrida, Dario</creatorcontrib><creatorcontrib>Manusia, Mario</creatorcontrib><creatorcontrib>Sapuppo, Giulia</creatorcontrib><creatorcontrib>Malandrino, Pasqualino</creatorcontrib><creatorcontrib>Vigneri, Riccardo</creatorcontrib><creatorcontrib>Pellegriti, Gabriella</creatorcontrib><title>Prognostic Factors for Adrenocortical Carcinoma Outcomes</title><title>Frontiers in endocrinology (Lausanne)</title><addtitle>Front Endocrinol (Lausanne)</addtitle><description>Adrenocortical carcinoma (ACC) is an aggressive tumor characterized by a high recurrence rate and poor response to treatment. This study analyzes a consecutive series of ACC patients to evaluate the prognostic value of various clinical and pathological characteristics. We retrospectively evaluated 32 ACC patients followed at our Medical Center from 1997 to 2015 and evaluated the prognostic value of age at diagnosis, gender, tumor functional status, stage, and type of treatment with respect to overall survival (OS) and disease-free survival (DFS), as determined by Kaplan-Meier curves. ACC was associated with hormonal overproduction in 50% of cases, and patients with isolated hyperandrogenism had a better prognosis. Recurrence was observed in 12/26 (46.2%) patients with no evidence of disease after surgery. Tumor size [hazard ratio (HR) 1.32, 95% confidential intervals (CI) 1.12-1.64; p = 0.007], ki-67 (HR 1.06, 95% CI 1.02-1.11; p = 0.009) and advanced stage at diagnosis (III-IV) (HR 6.51, 95% CI 1.65-24.68; p = 0.006) were associated with recurrence in the 26 R0 patients in the univariate analysis. Advanced stage was an independent risk factor for recurrence in the multivariate analysis (HR 8.10, 95% CI 1.55-41.35; p = 0.01). Five-year survival was 40.0%. Positive resection margins (HR 10.61, 95% CI 3.02-38.31; p = &lt; 0.001), ki-67 (HR 1.04, 95% CI 1.01-1.07; p = 0.01) and advanced stage (HR 11.31, 95% CI 1.45-87.76; p = 0.02) were associated with poor survival in all 32 patients, but only positive resection margins were an independent predictor of mortality in the multivariate analysis (HR 6.22, 95% CI 1.44-26.05; p = 0.01). ACC has a poor prognosis with a high recurrence rate. Tumor stage at diagnosis and the completeness of surgical excision are the most relevant prognostic factors.</description><subject>Endocrinology</subject><issn>1664-2392</issn><issn>1664-2392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVkM9LwzAUx4MobszdPUmPXjpfmh9NLsIYToXBPOg5pGkyK20zk1bwv7fbdMzTe_D98R4fhK4xzAgR8s7ZtvSzDDCfAYCUZ2iMOadpRmR2frKP0DTGj8ECFLCU4hKNspwBxcDHSLwEv2l97CqTLLXpfIiJ8yGZl8G23vgwCLpOFjqYqvWNTtZ9Z3xj4xW6cLqOdvo7J-ht-fC6eEpX68fnxXyVGiJ5l-ZacEEJOCIt5JoLmetSaGosLYwoRFYwZjSnDsBR4Sx3mS1y7DjmALlgZILuD73bvmhsaWzbBV2rbagaHb6V15X6r7TVu9r4L0UlE5zsCm5_C4L_7G3sVFNFY-tat9b3UWGBgTGWkXywwsFqgo8xWHc8g0HtmKs9c7VjrvbMh8jN6XvHwB9h8gPwiH54</recordid><startdate>20160725</startdate><enddate>20160725</enddate><creator>Scollo, Claudia</creator><creator>Russo, Marco</creator><creator>Trovato, Maria Antonietta</creator><creator>Sambataro, Daniela</creator><creator>Giuffrida, Dario</creator><creator>Manusia, Mario</creator><creator>Sapuppo, Giulia</creator><creator>Malandrino, Pasqualino</creator><creator>Vigneri, Riccardo</creator><creator>Pellegriti, Gabriella</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160725</creationdate><title>Prognostic Factors for Adrenocortical Carcinoma Outcomes</title><author>Scollo, Claudia ; Russo, Marco ; Trovato, Maria Antonietta ; Sambataro, Daniela ; Giuffrida, Dario ; Manusia, Mario ; Sapuppo, Giulia ; Malandrino, Pasqualino ; Vigneri, Riccardo ; Pellegriti, Gabriella</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-7a868430f39e07a6897ad8a4ce4bc8b82b55ca64f00f48fe6f2eb71f616007853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scollo, Claudia</creatorcontrib><creatorcontrib>Russo, Marco</creatorcontrib><creatorcontrib>Trovato, Maria Antonietta</creatorcontrib><creatorcontrib>Sambataro, Daniela</creatorcontrib><creatorcontrib>Giuffrida, Dario</creatorcontrib><creatorcontrib>Manusia, Mario</creatorcontrib><creatorcontrib>Sapuppo, Giulia</creatorcontrib><creatorcontrib>Malandrino, Pasqualino</creatorcontrib><creatorcontrib>Vigneri, Riccardo</creatorcontrib><creatorcontrib>Pellegriti, Gabriella</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Frontiers in endocrinology (Lausanne)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scollo, Claudia</au><au>Russo, Marco</au><au>Trovato, Maria Antonietta</au><au>Sambataro, Daniela</au><au>Giuffrida, Dario</au><au>Manusia, Mario</au><au>Sapuppo, Giulia</au><au>Malandrino, Pasqualino</au><au>Vigneri, Riccardo</au><au>Pellegriti, Gabriella</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Factors for Adrenocortical Carcinoma Outcomes</atitle><jtitle>Frontiers in endocrinology (Lausanne)</jtitle><addtitle>Front Endocrinol (Lausanne)</addtitle><date>2016-07-25</date><risdate>2016</risdate><volume>7</volume><spage>99</spage><epage>99</epage><pages>99-99</pages><issn>1664-2392</issn><eissn>1664-2392</eissn><abstract>Adrenocortical carcinoma (ACC) is an aggressive tumor characterized by a high recurrence rate and poor response to treatment. This study analyzes a consecutive series of ACC patients to evaluate the prognostic value of various clinical and pathological characteristics. We retrospectively evaluated 32 ACC patients followed at our Medical Center from 1997 to 2015 and evaluated the prognostic value of age at diagnosis, gender, tumor functional status, stage, and type of treatment with respect to overall survival (OS) and disease-free survival (DFS), as determined by Kaplan-Meier curves. ACC was associated with hormonal overproduction in 50% of cases, and patients with isolated hyperandrogenism had a better prognosis. Recurrence was observed in 12/26 (46.2%) patients with no evidence of disease after surgery. Tumor size [hazard ratio (HR) 1.32, 95% confidential intervals (CI) 1.12-1.64; p = 0.007], ki-67 (HR 1.06, 95% CI 1.02-1.11; p = 0.009) and advanced stage at diagnosis (III-IV) (HR 6.51, 95% CI 1.65-24.68; p = 0.006) were associated with recurrence in the 26 R0 patients in the univariate analysis. Advanced stage was an independent risk factor for recurrence in the multivariate analysis (HR 8.10, 95% CI 1.55-41.35; p = 0.01). Five-year survival was 40.0%. Positive resection margins (HR 10.61, 95% CI 3.02-38.31; p = &lt; 0.001), ki-67 (HR 1.04, 95% CI 1.01-1.07; p = 0.01) and advanced stage (HR 11.31, 95% CI 1.45-87.76; p = 0.02) were associated with poor survival in all 32 patients, but only positive resection margins were an independent predictor of mortality in the multivariate analysis (HR 6.22, 95% CI 1.44-26.05; p = 0.01). ACC has a poor prognosis with a high recurrence rate. Tumor stage at diagnosis and the completeness of surgical excision are the most relevant prognostic factors.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>27504106</pmid><doi>10.3389/fendo.2016.00099</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-2392
ispartof Frontiers in endocrinology (Lausanne), 2016-07, Vol.7, p.99-99
issn 1664-2392
1664-2392
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4958635
source DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Endocrinology
title Prognostic Factors for Adrenocortical Carcinoma Outcomes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T04%3A00%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Factors%20for%20Adrenocortical%20Carcinoma%20Outcomes&rft.jtitle=Frontiers%20in%20endocrinology%20(Lausanne)&rft.au=Scollo,%20Claudia&rft.date=2016-07-25&rft.volume=7&rft.spage=99&rft.epage=99&rft.pages=99-99&rft.issn=1664-2392&rft.eissn=1664-2392&rft_id=info:doi/10.3389/fendo.2016.00099&rft_dat=%3Cproquest_pubme%3E1810555237%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1810555237&rft_id=info:pmid/27504106&rfr_iscdi=true